Antiangiogenics
Antiangiogenic agents are compounds which prevent angiogenesis in vitro and/or in vivo. Angiogenesis inhibitors may be endogenous or synthetic; others are obtained from diet, for example resveratrol.
Antiangiogenic Inhibitors |
|
|---|---|
| Cat. No. | 产品名称/活性 |
| 6305 | Lenalidomide |
| Angiogenesis inhibitor; also TNF-α inhibitor and cereblon binder | |
| 6302 | Pomalidomide |
| Antiangiogenic; also TNF-α inhibitor and cereblon ubiquitination inhibitor | |
| 6187 | SK 216 |
| Angiogenesis inhibitor; Also PAI-1 inhibitor | |
| 6498 | TASP 0277308 |
| Potent and selective S1P1 receptor antagonist; inhibits angiogenesis | |
Other |
|
| Cat. No. | 产品名称/活性 |
| 5121 | 3PO |
| PFKFB3 inhibitor; antiangiogenic | |
| 5617 | AZD 1480 |
| Potent and selective JAK2 inhibitor; antiangiogenic | |
| 5029 | CHC |
| Monocarboxylic acid transport (MCT) inhibitor; displays anti-angiogenic activities | |
| 1629 | Herbimycin A |
| Antiangiogenic. Inhibits Src family kinases and Hsp90 | |
| 5981 | Itraconazole |
| SMO antagonist; antiangiogenic | |
| 5260 | KG 5 |
| Antiangiogenic; PDGFRβ, B-Raf, c-Raf, FLT3 and KIT inhibitor | |
| 4664 | Obtustatin |
| Potent and selective α1β1 inhibitor; antiangiogenic | |
| 2710 | OGT 2115 |
| Antiangiogenic. Heparanase inhibitor | |
| 2954 | PX 12 |
| Thioredoxin-1 inhibitor; attenuates expression of HIF-1α | |
| 1418 | Resveratrol |
| Cyclooxygenase inhbitor | |
| 0652 | Thalidomide |
| Antiangiogenic; also inhibits TNF-α synthesis | |
| 1098 | Tranilast |
| Antiangiogenic | |
Literature for Antiangiogenics
Tocris offers the following scientific literature for Antiangiogenics to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Angiogenesis in Cancer Poster
This poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.
Angiogenesis in Cancer Life Science Poster
Our Angiogenesis in Cancer poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.
Request copyDownload PDF